EveryLife Foundation for Rare Diseases

EveryLife Foundation for Rare Diseases
Name	EveryLife Foundation for Rare Diseases
Formation	2009
Type	Nonprofit organization
Headquarters	Washington, D.C.
Region served	United States
Purpose	Rare disease advocacy, policy, research support

EveryLife Foundation for Rare Diseases is a Washington, D.C.–based nonprofit organization focused on advocacy, policy development, and research support for rare disease communities. It engages with legislative bodies, regulatory agencies, patient groups, and scientific institutions to advance treatments, diagnostics, and access to care. The organization works alongside a broad coalition of stakeholders including patient advocates, researchers, philanthropists, and industry partners to influence public policy and funding priorities.

History

Founded in 2009 amid rising attention to orphan drug development and patient advocacy, the organization emerged during debates involving Food and Drug Administration, National Institutes of Health, Patient Protection and Affordable Care Act, and evolving regulatory frameworks. Early supporters included advocates connected to networks such as Global Genes, National Organization for Rare Disorders, and family-led groups similar to Undiagnosed Diseases Network advocates. Over successive administrations and congressional sessions, the group engaged with committees such as the United States Senate Committee on Health, Education, Labor, and Pensions and the United States House Committee on Energy and Commerce while interacting with agencies like the Centers for Medicare & Medicaid Services and stakeholders from Pharmaceutical Research and Manufacturers of America.

Mission and Programs

The foundation’s mission emphasizes accelerating research, improving regulatory pathways, and ensuring patient access, aligning with initiatives from entities such as the Office of Management and Budget, National Academy of Medicine, and international partners like the European Medicines Agency. Programs include policy fellowships, grassroots mobilization similar to campaigns run by March of Dimes and Susan G. Komen, and convenings modeled after symposiums at institutions like Johns Hopkins University and Harvard Medical School. The group coordinates with advisory boards composed of experts affiliated with Stanford University, Massachusetts Institute of Technology, and clinicians from centers such as Mayo Clinic.

Advocacy and Policy Initiatives

Advocacy work targets legislation and regulatory guidance affecting orphan products, drawing on precedents from the Orphan Drug Act and amendments influenced by hearings featuring witnesses from Rare Disease Legislative Advocates and patient testimony before panels including the House Ways and Means Committee. The foundation has provided input on rulemaking by the Food and Drug Administration and reimbursement policies at Centers for Medicare & Medicaid Services, while participating in coalitions with Biotechnology Industry Organization and patient coalitions affiliated with European Organization for Rare Diseases. It conducts lobbying, testimony, and policy briefs comparable to efforts by American Medical Association and Association of American Physicians and Surgeons on specialty issues such as accelerated approval, real-world evidence standards, and gene therapy regulation discussed in forums like BIO International Convention.

Research and Education Support

The organization funds and facilitates research collaborations linking investigators from universities including University of Pennsylvania, University of California, San Francisco, and Columbia University with clinician-researchers at hospitals such as Children's Hospital of Philadelphia and Cleveland Clinic. Educational programs mirror workshops hosted by National Institutes of Health institutes and professional societies like the American Society of Gene & Cell Therapy and American Thoracic Society, offering training for patient advocates, researchers, and regulatory professionals. It promotes data-sharing initiatives akin to those of the All of Us Research Program and supports registries modeled after Cleveland Clinic Registry efforts to improve natural history studies and trial readiness.

Partnerships and Funding

Funding streams combine philanthropic grants, corporate sponsorships, and foundation support from donors comparable to Bill & Melinda Gates Foundation, Chan Zuckerberg Initiative, and disease-specific philanthropies such as Cystic Fibrosis Foundation. Strategic partnerships include alliances with academic hubs like Yale School of Medicine, industry partners from Genentech, and nonprofit networks such as Rare Charitable Research Reserve affiliates. The foundation’s fundraising and stewardship practices reflect collaboration patterns seen with Alliance for Lupus Research and consortiums convened by Howard Hughes Medical Institute.

Impact and Notable Achievements

Notable achievements include contributing to policy changes that influenced orphan drug incentives reminiscent of reforms debated by United States Congress and informing guidance documents at the Food and Drug Administration that affect accelerated approval pathways. The foundation has helped train advocates who have testified before bodies such as United States Senate Committee on Appropriations and contributed to multi-stakeholder reports alongside National Academies of Sciences, Engineering, and Medicine. Its convenings have brought together leaders from Biogen, Regeneron Pharmaceuticals, academic centers like Brown University, and patient organizations like Genetic and Rare Diseases Information Center to advance translational research and access initiatives.

Category:Non-profit organizations based in Washington, D.C. Category:Patient advocacy Category:Rare disease organizations